For research use only. Not for therapeutic Use.
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor[1].
Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer’s disease[2].
| Catalog Number | I015000 |
| CAS Number | 1357362-02-7 |
| Synonyms | 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine |
| Molecular Formula | C19H20N4O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H20N4O2/c20-19-23-22-18(25-19)11-21-17-10-16(17)14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16-17,21H,10-12H2,(H2,20,23)/t16-,17+/m0/s1 |
| InChIKey | XBBRLCXCBCZIOI-DLBZAZTESA-N |
| SMILES | C1C(C1NCC2=NN=C(O2)N)C3=CC=C(C=C3)OCC4=CC=CC=C4 |
| Reference | [1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases [2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018. |
